The efficiency of treatment of human infections with the unicellular eukaryotic pathogens
such as fungi and protozoa remains deeply unsatisfactory. For example, the mortality rates …

With some advances in modern medicine (such as cancer chemotherapy, broad exposure to
antibiotics, and immunosuppression), the incidence of opportunistic fungal pathogens such …

Antifungal prophylaxis can reduce morbidity and mortality from invasive fungal disease
(IFD). However, its use needs to be optimised and appropriately targeted to patients at …

With the advent of newer antifungals, optimum treatment of mucormycosis remains to be fully
elucidated. This study systematically evaluated the contemporary management and …

The incidence rate of invasive mucormycosis (IM) in patients with hematological
malignancies (HMs) is increasing year by year, ranging from 0.07% to 4.29%, and the …

Objectives A two-part (Phase 1B/3), sequential, open-label, multicentre study evaluated the
pharmacokinetics (PK) and safety of intravenous (iv) posaconazole given as antifungal …

Prophylaxis and treatment of invasive fungal diseases in high-risk haematology patients is a
rapidly evolving field. Critical clinical questions remain unanswered, especially regarding …

Introduction: Antifungal agents can be co-administered alongside several other medications
for a variety of reasons such as the presence of comorbidities. Pharmacodynamic …

Trends in Medical Mycology (TIMM) is the biennial meeting of the Infectious Disease Group
of the European Organisation for Research and Treatment of Cancer (EORTC) and the …

ABSTRACT Introduction: Invasive fungal diseases (IFDs) are a major cause of morbidity and
mortality in patients undergoing allogeneic hematopoietic stem cell transplant (HSCT) …